KR20180129825A - 엑세나타이드 유사체의 연장된 방출 컨쥬게이트 - Google Patents

엑세나타이드 유사체의 연장된 방출 컨쥬게이트 Download PDF

Info

Publication number
KR20180129825A
KR20180129825A KR1020187029780A KR20187029780A KR20180129825A KR 20180129825 A KR20180129825 A KR 20180129825A KR 1020187029780 A KR1020187029780 A KR 1020187029780A KR 20187029780 A KR20187029780 A KR 20187029780A KR 20180129825 A KR20180129825 A KR 20180129825A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
peptide
agonist
arylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020187029780A
Other languages
English (en)
Korean (ko)
Inventor
에릭 엘. 슈나이더
브라이언 헤른
제프리 씨. 헤니스
개리 더블유. 애슐리
다니엘 브이. 산티
Original Assignee
프로린크스 엘엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로린크스 엘엘시 filed Critical 프로린크스 엘엘시
Publication of KR20180129825A publication Critical patent/KR20180129825A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187029780A 2016-03-16 2017-03-16 엑세나타이드 유사체의 연장된 방출 컨쥬게이트 Abandoned KR20180129825A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662309330P 2016-03-16 2016-03-16
US62/309,330 2016-03-16
US201662416058P 2016-11-01 2016-11-01
US62/416,058 2016-11-01
PCT/US2017/022791 WO2017161174A1 (en) 2016-03-16 2017-03-16 Extended release conjugates of exenatide analogs

Publications (1)

Publication Number Publication Date
KR20180129825A true KR20180129825A (ko) 2018-12-05

Family

ID=59852218

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029780A Abandoned KR20180129825A (ko) 2016-03-16 2017-03-16 엑세나타이드 유사체의 연장된 방출 컨쥬게이트

Country Status (13)

Country Link
US (1) US20200164083A1 (https=)
EP (2) EP3429608A4 (https=)
JP (1) JP7017248B2 (https=)
KR (1) KR20180129825A (https=)
CN (1) CN109414469A (https=)
AU (2) AU2017234680A1 (https=)
BR (1) BR112018068639A2 (https=)
CA (1) CA3016814A1 (https=)
MX (1) MX2018011149A (https=)
RU (1) RU2764547C2 (https=)
SG (1) SG11201807832VA (https=)
WO (1) WO2017161174A1 (https=)
ZA (2) ZA201805953B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102716759B1 (ko) 2023-12-20 2024-10-15 (주)인벤티지랩 엑세나타이드를 포함하는 서방형 주사제 조성물 및 이의 제조 방법

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745456B2 (en) * 2015-04-01 2020-08-18 The Scripps Research Institute Methods and compositions related to GPCR agonist polypeptides
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
CN119970617A (zh) 2019-04-05 2025-05-13 普罗林科斯有限责任公司 改良偶联接头
MX2022001528A (es) * 2019-08-07 2022-03-11 Prolynx Llc Esterilizacion con vapor de hidrogeles reticulados por enlazadores beta-eliminativos.
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
AU2022205377A1 (en) 2021-01-08 2023-07-20 Cellanome, Inc. Devices and methods for analyzing biological samples
US12576400B2 (en) 2021-01-08 2026-03-17 Cellanome, Inc. Methods for incubating and analyzing a cell in a compartment of a fluidic device
WO2025128916A1 (en) * 2023-12-13 2025-06-19 Cellanome, Inc. Devices and methods for analyzing biological samples
WO2026020143A1 (en) * 2024-07-19 2026-01-22 Prolynx Llc Extended-release conjugates of lipidated peptides, and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278589T3 (es) * 1999-01-14 2007-08-16 Amylin Pharmaceuticals, Inc. Excendinas destinadas a la inhibicion de glucagon.
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
CN100540565C (zh) * 2005-01-14 2009-09-16 无锡宏创医药科技有限公司 修饰的Exendins及其应用
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN101125207B (zh) * 2006-11-14 2012-09-05 上海华谊生物技术有限公司 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
ES2672526T3 (es) 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
WO2010017215A2 (en) * 2008-08-04 2010-02-11 The Regents Of The University Of California Biodegradable microspheres and methods of use thereof
PT3345593T (pt) * 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
EP2566334B1 (en) * 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
WO2011156407A2 (en) * 2010-06-09 2011-12-15 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists to treat pancre-atitis
CA2848142C (en) 2011-09-07 2021-05-18 Prolynx Llc Hydrogels with biodegradable crosslinking
US20140256626A1 (en) * 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102716759B1 (ko) 2023-12-20 2024-10-15 (주)인벤티지랩 엑세나타이드를 포함하는 서방형 주사제 조성물 및 이의 제조 방법

Also Published As

Publication number Publication date
CN109414469A (zh) 2019-03-01
ZA201905787B (en) 2021-03-31
AU2021232810A1 (en) 2021-10-14
RU2764547C2 (ru) 2022-01-18
AU2017234680A1 (en) 2018-10-11
AU2017234680A2 (en) 2018-12-13
MX2018011149A (es) 2019-05-30
CA3016814A1 (en) 2017-09-21
EP3429608A1 (en) 2019-01-23
EP3429608A4 (en) 2019-12-11
BR112018068639A2 (pt) 2019-07-30
WO2017161174A1 (en) 2017-09-21
RU2018136200A (ru) 2020-04-16
EP3922269A1 (en) 2021-12-15
JP7017248B2 (ja) 2022-02-08
RU2018136200A3 (https=) 2020-12-25
US20200164083A1 (en) 2020-05-28
ZA201805953B (en) 2019-11-27
SG11201807832VA (en) 2018-10-30
JP2019511497A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
JP7017248B2 (ja) エキセナチド類似体の持続放出コンジュゲート
AU2020277290B2 (en) Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist
CN103338790B (zh) 用聚乙二醇或其衍生物聚乙二醇化的唾液素‑4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物
EP3666792B1 (en) Insulin receptor partial agonists
JP4044140B2 (ja) インスリン誘導体類とその使用
JP4113778B2 (ja) 真性糖尿病の治療方法
EP2710031B1 (en) Improved peptide pharmaceuticals for insulin resistance
EP3922260A2 (en) Insulin receptor partial agonists and glp-1 analogues
US10413594B2 (en) Conjugates of somatostatin analogues
JP2016504335A (ja) Ａｐｊ受容体アゴニストおよびその使用
CN104114575B (zh) 具有降血糖作用的化合物、组合物及其用途
TW201004649A (en) A polypeptide complex comprising non-peptidyl polymer having three functional ends
CN101111268A (zh) 多肽和五糖的偶联物
CN109789221A (zh) 控释pth化合物中的递增剂量发现
JP2022504596A (ja) ヒトアミリンアナログペプチド及び使用方法
KR101104574B1 (ko) 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
WO2025112258A1 (zh) 一种实现多肽口服吸收的组合物
HK40064590A (en) Extended release conjugates of exenatide analogs
NZ786229A (en) Extended release conjugates of exenatide analogs
RU2839688C2 (ru) Полипептиды аналога амилина человека и способы их применения
EP4640210A1 (en) Formulation containing immunoactive interleukin 2 analog conjugate
Zhang et al. Exendin-4 and Its Derivatives for Diabetes and Obesity: Old Story and New Hope
EA041034B1 (ru) Частичные агонисты инсулинового рецептора

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904